DPP-4 Inhibitors: the wide capability of the oral therapy of the diabetes mellitus type 2

• Alexander S. Ametov
• Liudmila L. Kamynina

AbstractThe paper discusses the features of the diabetes mellitus type 2 management when DPP-4 inhibitor linagliptin is included in the glucose-lowering therapy for the different clinical groups – the elderly patients and the patients with the renal and hepatic impairment and the cardiovascular disorders. The results of the meta-analyses and the large randomized clinical trials confirm the efficacy and safety of usage of linagliptin in a clinical practice are reported.

Keywords:diabetes mellitus type 2, DPP-4 inhibitors, linagliptin, microalbuminuria, CAROLINA, MARLINA, CARMELINA

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)